[go: up one dir, main page]

PT2277890E - Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma - Google Patents

Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma Download PDF

Info

Publication number
PT2277890E
PT2277890E PT97506695T PT09750669T PT2277890E PT 2277890 E PT2277890 E PT 2277890E PT 97506695 T PT97506695 T PT 97506695T PT 09750669 T PT09750669 T PT 09750669T PT 2277890 E PT2277890 E PT 2277890E
Authority
PT
Portugal
Prior art keywords
peptide
interest
plasma
life
extending half
Prior art date
Application number
PT97506695T
Other languages
English (en)
Inventor
Wakabayashi Naomi
Sato Seiji
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PT2277890E publication Critical patent/PT2277890E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/63Motilins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT97506695T 2008-05-23 2009-05-22 Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma PT2277890E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008136106 2008-05-23

Publications (1)

Publication Number Publication Date
PT2277890E true PT2277890E (pt) 2016-03-31

Family

ID=41340233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97506695T PT2277890E (pt) 2008-05-23 2009-05-22 Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma

Country Status (16)

Country Link
US (1) US8551937B2 (pt)
EP (1) EP2277890B1 (pt)
JP (1) JP5524049B2 (pt)
KR (2) KR101350251B1 (pt)
CN (1) CN101809029B (pt)
BR (1) BRPI0904622A2 (pt)
CA (1) CA2698582C (pt)
CY (1) CY1117478T1 (pt)
DK (1) DK2277890T3 (pt)
ES (1) ES2566830T3 (pt)
HR (1) HRP20160303T1 (pt)
HU (1) HUE028539T2 (pt)
PL (1) PL2277890T3 (pt)
PT (1) PT2277890E (pt)
SI (1) SI2277890T1 (pt)
WO (1) WO2009142307A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
EP2432489B1 (en) * 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
CN107261119A (zh) 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
KR20140054084A (ko) * 2011-08-19 2014-05-08 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약
JPWO2013099376A1 (ja) * 2011-12-26 2015-04-30 国立大学法人福井大学 体外受精における成熟卵子マーカー及びその使用
KR20150013455A (ko) 2012-04-25 2015-02-05 다이이찌 산쿄 가부시키가이샤 골 수복 촉진제
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
WO2015129812A1 (ja) * 2014-02-27 2015-09-03 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc 治療用ビタミンdコンジュゲート
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3964522A1 (en) * 2015-11-16 2022-03-09 Ubiprotein, Corp. A method for extending half-life of a protein
PL3400019T3 (pl) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
NZ743489A (en) * 2016-01-08 2022-09-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US20190218274A1 (en) * 2016-05-06 2019-07-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018139464A1 (ja) 2017-01-24 2018-08-02 第一三共株式会社 低身長症治療剤
WO2018175534A1 (en) * 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP4393502A2 (en) * 2018-12-26 2024-07-03 Skinmed Co., Ltd. Acetylcholine receptor inhibitory peptides and uses thereof
KR20220019785A (ko) 2019-06-12 2022-02-17 노파르티스 아게 나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
JP2024506912A (ja) 2021-02-12 2024-02-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024162772A1 (ko) * 2023-02-01 2024-08-08 주식회사 에이티지씨 생체 내 지속성이 증가된 생리활성물질의 결합체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトcnp遺伝子及び前駆体蛋白
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
IL147652A0 (en) 1999-07-23 2002-08-14 Kangawa Kenji Novel peptides
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
CN101519449A (zh) * 2001-08-30 2009-09-02 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
RU2420306C2 (ru) * 2005-11-21 2011-06-10 Юниверсити Оф Миязаки ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ДЛЯ УСКОРЕННОГО ЗАЖИВЛЕНИЯ КОЖИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ГРЕЛИН И ЕГО ПРОИЗВОДНЫЕ ИЛИ ВЕЩЕСТВО, ВОЗДЕЙСТВУЮЩЕЕ НА РЕЦЕПТОР GHS-R1a
JPWO2007058360A1 (ja) * 2005-11-21 2009-05-07 国立大学法人 宮崎大学 デスアシルグレリン及びその誘導体を有効成分とする皮膚修復促進治療剤
CN101516399A (zh) * 2006-08-11 2009-08-26 国立大学法人宫崎大学 以去酰基化的生长素释放肽及其衍生物作为有效成分的脊髓神经修复促进治疗剂
KR20090060291A (ko) 2006-08-11 2009-06-11 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 그렐린 및 그 유도체 또는 GHS―R1a에 작용하는 물질을 유효성분으로 포함하는 척수 신경 수복 촉진 치료제
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks

Also Published As

Publication number Publication date
DK2277890T3 (en) 2016-02-08
SI2277890T1 (sl) 2016-04-29
CN101809029B (zh) 2016-06-15
US20100305031A1 (en) 2010-12-02
CA2698582A1 (en) 2009-11-26
ES2566830T3 (es) 2016-04-15
WO2009142307A1 (ja) 2009-11-26
KR20130018965A (ko) 2013-02-25
CY1117478T1 (el) 2017-04-26
PL2277890T3 (pl) 2016-06-30
HUE028539T2 (en) 2016-12-28
EP2277890B1 (en) 2016-01-06
EP2277890A4 (en) 2011-08-24
JP5524049B2 (ja) 2014-06-18
US8551937B2 (en) 2013-10-08
CN101809029A (zh) 2010-08-18
KR101350251B1 (ko) 2014-01-14
KR20100038236A (ko) 2010-04-13
EP2277890A1 (en) 2011-01-26
JPWO2009142307A1 (ja) 2011-09-29
HRP20160303T1 (hr) 2016-04-22
BRPI0904622A2 (pt) 2016-06-21
CA2698582C (en) 2016-09-13

Similar Documents

Publication Publication Date Title
PT2277890E (pt) Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma
HK1250042A1 (zh) 溶酶體靶向肽及其應用
GB0914110D0 (en) Peptide libraries
GB0913775D0 (en) Multispecific peptides
EP2131390A4 (en) PLASMA PROCESSOR
HK1214177A1 (zh) 用於癌症的肽治療劑
PL2421884T3 (pl) Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje
IL216223A0 (en) Methods of analyzing peptide mixtures
GB0920981D0 (en) Peptides
GB2462761B (en) Protein formulation
EP2373272A4 (en) STALL ARTICLE
TWI319863B (en) Plasma display
EP2270141A4 (en) Lacritin PART PEPTIDE
HK1217912A1 (zh) 控釋肽製劑
EP2123666A4 (en) PEPTIDE
IL216199A (en) A peptide containing the sequence ednimvtfrnqasr
EP2478010A4 (en) PART PEPTIDE OF LACRITINE
GB0724953D0 (en) Methods of peptide modification
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
ZA201203722B (en) Peptide
EP2504065A4 (en) STABLE MIXTURES AND RELATED METHODS
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS
GB0920987D0 (en) Peptides
GB0817978D0 (en) Peptides